90 related articles for article (PubMed ID: 16467117)
1. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors.
Shin I; Miller T; Arteaga CL
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1008s-1012s. PubMed ID: 16467117
[TBL] [Abstract][Full Text] [Related]
2. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
3. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
[TBL] [Abstract][Full Text] [Related]
4. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Sonne-Hansen K; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
[TBL] [Abstract][Full Text] [Related]
5. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Macedo LF; Guo Z; Tilghman SL; Sabnis GJ; Qiu Y; Brodie A
Cancer Res; 2006 Aug; 66(15):7775-82. PubMed ID: 16885381
[TBL] [Abstract][Full Text] [Related]
6. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
7. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
8. Estrogen-related receptor alpha expression and function is associated with the transcriptional coregulator AIB1 in breast carcinoma.
Heck S; Rom J; Thewes V; Becker N; Blume B; Sinn HP; Deuschle U; Sohn C; Schneeweiss A; Lichter P
Cancer Res; 2009 Jun; 69(12):5186-93. PubMed ID: 19491275
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
10. Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators.
Weldon CB; Elliott S; Zhu Y; Clayton JL; Curiel TJ; Jaffe BM; Burow ME
Surgery; 2004 Aug; 136(2):346-54. PubMed ID: 15300201
[TBL] [Abstract][Full Text] [Related]
11. Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells.
Su Q; Hu S; Gao H; Ma R; Yang Q; Pan Z; Wang T; Li F
Oncology; 2008; 75(3-4):159-68. PubMed ID: 18827493
[TBL] [Abstract][Full Text] [Related]
12. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
13. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
Foster PA; Chander SK; Newman SP; Woo LW; Sutcliffe OB; Bubert C; Zhou D; Chen S; Potter BV; Reed MJ; Purohit A
Clin Cancer Res; 2008 Oct; 14(20):6469-77. PubMed ID: 18927286
[TBL] [Abstract][Full Text] [Related]
14. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATP-independent manner by the REGgamma proteasome.
Li X; Lonard DM; Jung SY; Malovannaya A; Feng Q; Qin J; Tsai SY; Tsai MJ; O'Malley BW
Cell; 2006 Jan; 124(2):381-92. PubMed ID: 16439211
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells.
Prosperi JR; Robertson FM
Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):55-70. PubMed ID: 16997132
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.
Hsu MC; Chang HC; Hung WC
Endocr Relat Cancer; 2007 Sep; 14(3):655-67. PubMed ID: 17914096
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer.
Márquez DC; Chen HW; Curran EM; Welshons WV; Pietras RJ
Mol Cell Endocrinol; 2006 Feb; 246(1-2):91-100. PubMed ID: 16388889
[TBL] [Abstract][Full Text] [Related]
18. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1.
Lattrich C; Juhasz-Boess I; Ortmann O; Treeck O
Oncol Rep; 2008 Mar; 19(3):811-7. PubMed ID: 18288420
[TBL] [Abstract][Full Text] [Related]
19. AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.
Zhao W; Zhang Q; Kang X; Jin S; Lou C
Biochem Biophys Res Commun; 2009 Mar; 380(3):699-704. PubMed ID: 19285025
[TBL] [Abstract][Full Text] [Related]
20. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
